BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT

Novavax Inc. (NASDAQ:NVAX) is one of the best cheap stocks with huge upside potential. On June 11, BTIG maintained a Buy rating on Novavax Inc. (NASDAQ:NVAX) with a $19 price target.

Novavax Inc. (NVAX): Among Unstoppable Stocks That Could Double Your Money

A closeup of a vial of the biotechnology company’s vaccines.

BTIG analyst Thomas Shrader told investors following the company’s announcement of the results of the initial cohort of its COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza Phase 3 trial that the primary goal was to exhibit that the immunogenicity of both the COVID-19 and Influenza vaccines was within the protective range with  “interference” not being a strong factor.

He stated that the first CIC data “looks unremarkable – exactly what we hoped for,” adding that the “most positive signs from today’s data” were stronger immunogenicity for the Novavax flu vaccine for some antigens compared to the “gold-standard” flu vaccine FLUZONE-HD.

Novavax Inc. (NASDAQ:NVAX) is a biotechnology company that discovers, develops, and commercializes recombinant vaccines.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.